Lurasidone for the acute treatment of adults with schizophrenia: What is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?

Clinical Schizophrenia and Related Psychoses

Volumn 6, Issue 2, 2012, Pages 76-85

  Citrome, Leslie ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Efficacy; Lurasidone; Number needed to harm; Number needed to treat; Safety; Schizophrenia; Tolerability

Indexed keywords

GLUCOSE; HALOPERIDOL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LURASIDONE; OLANZAPINE; PLACEBO; QUETIAPINE; TRIACYLGLYCEROL;

ADULT; AGITATION; AKATHISIA; ANXIETY; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; GLUCOSE BLOOD LEVEL; HEADACHE; HUMAN; INSOMNIA; NAUSEA; NUMBERS NEEDED TO TREAT; OUTCOME ASSESSMENT; PARKINSONISM; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POSITIVE AND NEGATIVE SYNDROME SCALE; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOMNOLENCE; TRIACYLGLYCEROL BLOOD LEVEL; VOMITING; WEIGHT GAIN;

ADULT; AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BLOOD GLUCOSE; CHOLESTEROL; DIBENZOTHIAZEPINES; DISORDERS OF EXCESSIVE SOMNOLENCE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HALOPERIDOL; HUMANS; ISOINDOLES; LIKELIHOOD FUNCTIONS; MALE; MEDICATION ADHERENCE; NAUSEA; NUMBERS NEEDED TO TREAT; PSYCHIATRIC STATUS RATING SCALES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SCHIZOPHRENIA; THIAZOLES; TREATMENT OUTCOME; TRIGLYCERIDES; WEIGHT GAIN;

EID: 84864596474     PISSN: 19351232     EISSN: None     Source Type: Journal    
DOI: 10.3371/CSRP.6.2.5     Document Type: Article

References (19)

1. Sunovion. Latuda (lurasidone). Revised October 2010. Available from: http://www.latuda.com/LatudaPrescribingInformation.pdf [Last accessed 2011 May 24].
2. Nakamura M, Ogasa M, Guarino J, Phillips D, Severs J, Cucchiaro J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebocontrolled trial. J Clin Psychiatry 2009;70(6):829-836.
3. Meltzer HY, Cucchiaro J, Silva R, Ogasa M, Phillips D, Xu J, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry 2011;168(9):957-967.
4. Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. Int J Clin Pract 2011;65(2):189-210.
5. Citrome L. Lurasidone for schizophrenia: a brief review of a new secondgeneration antipsychotic. Clin Schizophr Relat Psychoses 2011;4(4):251-257.
6. Citrome L. Iloperidone, asenapine, and lurasidone: a brief overview of 3 new second-generation antipsychotics. Postgrad Med 2011;123(2):153-162.
7. Citrome L. Compelling or irrelevant? Using number needed to treat can help decide. Acta Psychiatr Scand 2008;117(6):412-419. (Pubitemid 351678479)
8. Citrome L. Number needed to treat: what it is and what it isn't, and why every clinician should know how to calculate it. J Clin Psychiatry 2011;72(3):412-413.
9. Citrome L. Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications. Curr Drug Saf 2009;4(3):229-237.
10. Citrome L. Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Postgrad Med 2010;122(4):39-48.
11. Citrome L, Kantrowitz J. Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks. Expert Rev Neurother 2008;8(7):1079-1091. (Pubitemid 351962075)
12. Straus SE. Individualizing treatment decisions. The likelihood of being helped or harmed. Eval Health Prof 2002;25(2):210-224. (Pubitemid 34507361)
13. Loebel A, Cucchiaro J, Sarma K, Xu J, Hsu J, Kalali AH, et al. Lurasidone in the treatment of acute schizophrenia: results of the double-blind, placebo-controlled, 6-week, PEARL 3 trial. Poster presentation NR06-38. American Psychiatric Association 164th Annual Meeting. Honolulu, HI, 2011 May 14-18.
14. Loebel A, Cucchiaro J, Ogasa M, Silva R, Pikalov AA, Hsu J, et al. Efficacy of lurasidone: summary of results from the clinical development program. Poster presentation II-45. NCDEU 50th Anniversary Meeting. Boca Raton, FL, 2010 June 14-17.
15. FDA. Drug Approval Package. Latuda (lurasidone hydrochloride) Tablets. 3 December 2010. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2010/ 200603Orig1s000TOC.cfm [Last accessed 2010 December 16].
16. Dainippon Sumitomo Pharma. Dainippon Sumitomo Pharma announces Pan-Asia study results for lurasidone, an atypical antipsychotic agent, in the treatment of schizophrenia. Press Release 2011 May 11. http://www.ds-pharma.com/news/pdf/ ene20110511-3.pdf [Last accessed 2012 January 03].
17. Kraemer HC, Kupfer DJ. Size of treatment effects and their importance to clinical research and practice. Biol Psychiatry 2006;59(11):990-996. (Pubitemid 43849650)
18. Citrome L, Nasrallah HA. On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not. Expert Opin Pharmacother 2001 Oct 22. [Epub ahead of print).
19. Citrome L. Relative vs. absolute measures of benefit and risk: what's the difference? Acta Psychiatr Scand 2010;121(2):94-102.